Board Member

Honorary President of Center Laboratories, Inc.

Mr. Jung-Chin (Rongjin) Lin has held several chief executive management roles in various pharmaceutical companies over the past 30 years. Mr. Lin’s specialty is strategic management for pharmaceutical and biotech industries and specializes in company restructuring, building pharmaceutical business strategies and establishing strategic management. He has successfully restructured and reorganized over 15 enterprises and is still actively engaged in distributing and integrating related investments in the biotech industry.

Mr. Lin is currently Honorary President of Center Laboratories, Inc. and Chairman of Lumosa Therapeutics Co., Ltd. in Taiwan. Mr. Lin transformed Center Labs from a multiple-dosage pharmaceutical company into a professional oral solution pharmaceutical, which drives over 70% market shares in Taiwan. In recent years, Center Labs, Inc. played a role as an Industrial Biotech Bank platform, which targets to invest and integrate more biotech companies. The new investing fields include new drug development, antibody engineering and protein design, cell line generation, biosimilar drug development and production, medical devices, nutrition, and agricultural biotech; investing regions cover the Greater China Region and other Asian countries such as Japan and Korea. In late 2014, Center Labs Inc. also acquired Ausnutria Dairy Corp, expanding the investment in the infant formula industry.

Mr. Lin received his B.S. degree in Pharmacy from the School of Pharmacy, Taipei Medical University, and was awarded Doctorate of Philosophy, Honoris Causa by Taipei Medical University in 2010.